Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;11:787814. doi: 10.3389/fonc.2021.787814

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Zheng, Sun, Yi, Zhang, Wang, Lan, Zhang, Xian and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

External validation of the prognostic significance of YAP1/MYC and their impact in MM therapies. (A) The comparison of YAP1/MYC mRNA expression levels in different developmental stages of MM. The x-axis represents case number/YAP1 count value/MYC count value from left to right while the y-axis represents case number/YAP1 count value/MYC count value from top to bottom. NPC: normal plasma cell; MGUS: monoclonal gammopathy of undetermined significance; sMM: smothering multiple myeloma; rMM: relapsed multiple myeloma. (B) Kaplan–Meier survival curves comparing the overall survival in MM cases with differential expression level of YAP1 and MYC in GSE9782 dataset (264 cases). (C) Kaplan–Meier survival curves comparing the overall survival in MM cases with differential expression level of YAP1 and MYC in the GSE2658 dataset (559 cases). (D) The survival rate of MM patients with high or low expression of YAP1 treated with different strategies. (E) The survival rate of YAP1-MYC+ MM patients versus others treated with IMiD.